glp-1 agonist or antagonist Structure-Based Discovery of Orthosteric Non-Peptide GLP-1R Agonists via Integrated Virtual Screening and Molecular Dynamics[v1] Agonist and antagonist activities of

Ready to Optimize Your Longevity

History [edit] Descriptions of deficiency effects [edit] Between 1849 and 1887, Thomas Addison described a case of pernicious anemia, William Osler and William Gardner first described a case of neuropathy, Hayem described large red cells in the peripheral blood in this condition, which he called "giant blood corpuscles" (now called macrocytes), Paul Ehrlich identified megaloblasts in the bone marrow, and Ludwig Lichtheim described a case of myelopathy

S., White, W., Jennings, M

Administration Routes and Techniques Most GLP-1 agonists are administered via subcutaneous injection, meaning the medication is injected into the fatty tissue just under the skin